|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM24399365X |
003 |
DE-627 |
005 |
20250217194423.0 |
007 |
cr uuu---uuuuu |
008 |
231224s2014 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.clim.2014.10.002
|2 doi
|
028 |
5 |
2 |
|a pubmed25n0813.xml
|
035 |
|
|
|a (DE-627)NLM24399365X
|
035 |
|
|
|a (NLM)25444722
|
035 |
|
|
|a (PII)S1521-6616(14)00238-1
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Wang, Yao
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
|
264 |
|
1 |
|c 2014
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 19.02.2015
|
500 |
|
|
|a Date Revised 08.01.2021
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a ClinicalTrials.gov: NCT01735604
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Copyright © 2014 Elsevier Inc. All rights reserved.
|
520 |
|
|
|a We conducted a trial testing a CD20-specific CAR coupled with CD137 and the CD3ζ moiety in patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL). Seven patients were enrolled. One of the two patients with no bulky tumor obtained a 14-month durable and ongoing complete remission by cell infusion only, and another attained a 6-month tumor regression. Four of five patients with bulky tumor burden were evaluable for clinical efficacy, three of which attained 3- to 6-month tumor regression. Delayed toxicities related to cell infusion are directly correlated to tumor burden and tumor-harboring sites, and mainly included cytokine release symptoms, tumor lysis symptoms, massive hemorrhage of the alimentary tract and aggressive intrapulmonary inflammation surrounding extranodal lesions. These results show firstly that anti-CD20 CART cells can cause prolonged tumor regression in combination with debulking conditioning regimens for advanced DLBCL. This study is registered at www.clinicaltrials.gov as NCT01735604
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
4 |
|a Anti-CD20 chimeric antigen receptor (CAR) T cells;
|
650 |
|
4 |
|a Delayed toxicities
|
650 |
|
4 |
|a Diffuse large B-cell lymphoma (DLBCL);
|
650 |
|
4 |
|a Refractory advanced;
|
650 |
|
7 |
|a Antigens, CD20
|2 NLM
|
650 |
|
7 |
|a Receptors, Antigen, T-Cell
|2 NLM
|
650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
650 |
|
7 |
|a Tumor Necrosis Factor Receptor Superfamily, Member 9
|2 NLM
|
700 |
1 |
|
|a Zhang, Wen-ying
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Han, Qing-wang
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Liu, Yang
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Dai, Han-ren
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Guo, Ye-lei
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Bo, Jian
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fan, Hui
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zhang, Yan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zhang, Ya-jing
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chen, Mei-xia
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Feng, Kai-chao
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Wang, Quan-shun
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fu, Xiao-bing
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Han, Wei-dong
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 155(2014), 2 vom: 04. Dez., Seite 160-75
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:155
|g year:2014
|g number:2
|g day:04
|g month:12
|g pages:160-75
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2014.10.002
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 155
|j 2014
|e 2
|b 04
|c 12
|h 160-75
|